Sequestosome 1/p62: across diseases
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Sequestosome 1/p62 is a signal modulator or adaptor protein involved in receptor-mediated signal transduction. Sequestosome 1/p62 is gaining attention as it is involved in several diseases including Parkinson disease, Alzheimer disease, liver and breast cancer, Paget's disease of bone, obesity and insulin resistance. In this review, we will focus on the most recent advances on the physiological function of p62 relevant to human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124 · cited 2×
“The loss of p62 reduces liver damage in Atg7 knockout mice (Komatsu et al. 2007; Jin et al. 2009), whereas characterization of liver-specific p62 overexpression in transgenic mice revealed a phenotype of a fatty liver with microvesicular fat distribution in p62 transgenic mice (Tybl et al. 2011).”
BackgroundJain, A., Lamark, T., Sjøttem, E., Bowitz Larsen, K., Atesoh Awuh, J., Øvervatn, A., McMahon, M., Hayes, J. D., & Johansen, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.118976 · Cited by 1,472
Autophagy-deficient mice develop multiple liver tumors
Takamura, A., Komatsu, M., Hara, T., Sakamoto, A., Kishi, C., Waguri, S., Eishi, Y., Hino, O., Tanaka, K., & Mizushima, N. (2011) · Genes & Development · doi:10.1101/gad.2016211 · Cited by 1,342 · cited 3×
“Autophagy deficient mice, however, develop multiple liver tumors and overexpress p62 protein in malignant tumor cells (Takamura et al. 2011).”
BackgroundInfluentialJoazeiro, C. A. P., & Weissman, A. M. (2000) · Cell · doi:10.1016/s0092-8674(00)00077-5 · Cited by 1,249 · cited 1×
“TRAF6 is a ubiquitin ligase E3 that can ubiquitinate several substrates (Joazeiro & Weissman 2000). p62 is known to bind polyubiquitinated substrates through its UBA domain and shuttles them to the proteasome for degradation through its PB1 domain (Seibenhener et al. 2004).”
BackgroundImpaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848 · cited 2×
“1993) and the ubiquitin mediated proteasome function was attenuated in AD (Keller et al. 2000).”
BackgroundPerry, G., Friedman, R., Shaw, G., & Chau, V (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3033 · Cited by 623 · cited 1×
“NFTs and distorted neuritis of NPs were found to be associated with ubiquitin (Perry et al. 1987).”
BackgroundRecurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.
Laurin, N., Brown, J. P., Morissette, J., & Raymond, V. (2002) · The American Journal of Human Genetics · doi:10.1086/340731 · Cited by 563 · cited 6×
“…2000). p62 harbors an amino terminal PB1 domain with an SH2 binding domain and an acidic interaction domain (AID) that binds the atypical PKC (aPKC) (Laurin et al. 2002), a ZZ finger, a binding site for the RING-finger protein tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6),…”
BackgroundResultInfluentialp62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria
Okatsu, K., Saisho, K., Shimanuki, M., Nakada, K., Shitara, H., Sou, Y., Kimura, M., Sato, S., Hattori, N., Komatsu, M., et al. (2010) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01426.x · Cited by 397 · cited 2×
“Ubiquitinated mitochondria shuttle through microtubules to form aggregates in the perinuclear region and are degraded by autophagy (Geisler et al. 2010; Okatsu et al. 2010).”
BackgroundInfluentialUbiquitin, cellular inclusions and their role in neurodegeneration
Alves-Rodrigues, A., Gregori, L., & Figueiredo-Pereira, M. E. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01276-4 · Cited by 393
Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Titani, K., & Ihara, Y. (1993) · Neuron · doi:10.1016/0896-6273(93)90063-w · Cited by 332
Durán, A., Serrano, M., Leitges, M., Flores, J. M., Picard, S., Brown, J. P., Moscat, J., & Diaz-Meco, M. T. (2004) · Developmental Cell · doi:10.1016/s1534-5807(03)00403-9 · Cited by 316 · cited 2×
“In addition, abnormal expression of both fetal RNA-binding protein and p62 is found in liver cancer and liver cirrhosis (Lu et al. 2001), and p62 has been identified as an important NF-κB mediator in tumorigenesis (Duran et al. 2004).”
BackgroundSequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation
Babu, J. R., Geetha, T., & Wooten, M. W. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03181.x · Cited by 315
Self-citationMature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62
Rodriguez, A., Durán, A., Selloum, M., Champy, M.-F., Diez-Guerra, F. J., Flores, J. M., Serrano, M., Auwerx, J., Diaz-Meco, M. T., & Moscat, J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.011 · Cited by 290 · cited 2×
“Deletion of the p62 gene increased ERK activation and adipogenesis could lead to obesity and insulin and leptin resistance (Rodriguez et al. 2006).”
BackgroundCopple, I. M., Lister, A., Obeng, A. D., Kitteringham, N. R., Jenkins, R. E., Layfield, R., Foster, B. J., Goldring, C. E., & Park, B. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.096545 · Cited by 260 · cited 1×
“Overproduction of p62 or autophagy deficiency competes with the interaction between Nrf2 and Keap1, resulting in stabilization of Nrf2 and transcriptional activation of Nrf2 target genes (Copple et al. 2010; Jain et al. 2010; Komatsu et al. 2010; Lau et al. 2010; Riley et al. 2010).”
BackgroundGenetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration
Ramesh Babu, J., Lamar Seibenhener, M., Peng, J., Strom, A., Kemppainen, R., Cox, N., Zhu, H., Wooten, M. C., Diaz‐Meco, M. T., Moscat, J., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05340.x · Cited by 258 · cited 4×
“Mice deficient in the p62 gene exhibit AD-like characteristics (Babu et al. 2008).”
BackgroundInfluentialKuusisto, E., Suuronen, T., & Salminen, A. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4107 · Cited by 131 · cited 5×
“Neuronal cell death or proteasomal dysfunction also leads to the accumulation of misfolded and ubiquitinated proteins (Kuusisto et al. 2001b) and causes increased expression of p62, which protects cells by localizing the misfolded proteins as aggregates in cytoplasmic inclusions (Zatloukal et al.…”
BackgroundInfluentialOxidative damage to the promoter region of SQSTM1/p62 is common to neurodegenerative disease
Du, Y., Wooten, M. C., & Wooten, M. W. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.015 · Cited by 96 · cited 2×
“In neurodegenerative diseases, oxidative damage to the p62 promoter reduced its expression (Du et al. 2009).”
BackgroundOverexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype
Tybl, E., Shi, F.-D., Kessler, S. M., Tierling, S., Walter, J., Bohle, R. M., Wieland, S., Zhang, J., Tan, E. M., & Kiemer, A. K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.034 · Cited by 65 · cited 1×
“The loss of p62 reduces liver damage in Atg7 knockout mice (Komatsu et al. 2007; Jin et al. 2009), whereas characterization of liver-specific p62 overexpression in transgenic mice revealed a phenotype of a fatty liver with microvesicular fat distribution in p62 transgenic mice (Tybl et al. 2011).”
Background
Cited by
Kaarniranta, K., Sinha, D., Blasiak, J., Kauppinen, A., Veréb, Z., Salminen, A., Boulton, M. E., & Petrovski, G. (2013) · Autophagy · doi:10.4161/auto.24546 · Cited by 326
Autolysosomal β‐catenin degradation regulates Wnt‐autophagy‐p62 crosstalk
Petherick, K. J., Williams, A. C., Lane, J. D., Ordóñez‐Morán, P., Huelsken, J., Collard, T. J., Smartt, H. J., Batson, J., Malik, K., Paraskeva, C., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.123 · Cited by 319
Yamada, T., Murata, D., Adachi, Y., Itoh, K., Kameoka, S., Igarashi, A., Kato, T., Araki, Y., Huganir, R. L., Dawson, T. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.014 · Cited by 290
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Rubino, E., Rainero, I., Chiò, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e25df · Cited by 286
Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology
Teyssou, E., Takeda, T., Lebon, V., Boillée, S., Doukouré, B., Bataillon, G., Sazdovitch, V., Cazeneuve, C., Meininger, V., LeGuern, E., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1090-0 · Cited by 241
“p62-Positive inclusions are common in many degenerative diseases including tauopathies and synucleinopathies [15, 26] and the key features in neuropathological diagnosis and classification of ALS and FTLD, both sporadic and familial [38, 41].”
Background
Metadata
- Authors
- Geetha, T., Viswaprakash, N., Sycheva, M., & Babu, J. R.
- Venue
- Biomarkers
- Publisher
- Informa UK Limited
- Published
- 2012-02
- Volume
- 17
- Issue
- 2
- Pages
- 99-103
- ISSN
- 1354-750X (ISSN-L)
- 1366-5804
- OpenAlex
- W2087794695
- Cited by
- 45
- References
- 18
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.